-
Something wrong with this record ?
Multipotency and therapeutic potential of NG2 cells
M. Valny, P. Honsa, J. Kriska, M. Anderova,
Language English Country Great Britain
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
- MeSH
- Antigens metabolism MeSH
- Stem Cells drug effects physiology MeSH
- Central Nervous System Agents pharmacology therapeutic use MeSH
- Humans MeSH
- Intercellular Signaling Peptides and Proteins metabolism MeSH
- Multipotent Stem Cells drug effects physiology transplantation MeSH
- Neurogenesis drug effects physiology MeSH
- Neuroglia drug effects physiology MeSH
- Neuronal Plasticity drug effects physiology MeSH
- Oligodendroglia drug effects physiology MeSH
- Cell Proliferation drug effects physiology MeSH
- Proteoglycans metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
NG2 cells represent one of the most proliferative glial cell populations in the intact mammalian central nervous system (CNS). They are well-known for their ability to renew themselves or to generate new oligodendrocytes during development as well as in adulthood, therefore also being termed oligodendrocyte progenitor cells. Following CNS injuries, such as demyelination, trauma or ischemia, the proliferative capacity of NG2 cells rapidly increases and moreover, their differentiation potential broadens, as documented by numerous reports also describing their differentiation into astrocytes or even neurons. Here, we summarize the current knowledge about NG2 cells proliferation, their fate plasticity during embryogenesis as well as in postnatal CNS under physiological and pathological conditions, with the main emphasis on the role of various signaling molecules, growth factors, hormones or even neurotransmitters on the fate potential of NG2 cells.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016599
- 003
- CZ-PrNML
- 005
- 20180521123356.0
- 007
- ta
- 008
- 180515s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bcp.2017.05.008 $2 doi
- 035 __
- $a (PubMed)28522408
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Valny, Martin $u Department of Cellular Neurophysiology, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 245 10
- $a Multipotency and therapeutic potential of NG2 cells / $c M. Valny, P. Honsa, J. Kriska, M. Anderova,
- 520 9_
- $a NG2 cells represent one of the most proliferative glial cell populations in the intact mammalian central nervous system (CNS). They are well-known for their ability to renew themselves or to generate new oligodendrocytes during development as well as in adulthood, therefore also being termed oligodendrocyte progenitor cells. Following CNS injuries, such as demyelination, trauma or ischemia, the proliferative capacity of NG2 cells rapidly increases and moreover, their differentiation potential broadens, as documented by numerous reports also describing their differentiation into astrocytes or even neurons. Here, we summarize the current knowledge about NG2 cells proliferation, their fate plasticity during embryogenesis as well as in postnatal CNS under physiological and pathological conditions, with the main emphasis on the role of various signaling molecules, growth factors, hormones or even neurotransmitters on the fate potential of NG2 cells.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antigeny $x metabolismus $7 D000941
- 650 _2
- $a proliferace buněk $x účinky léků $x fyziologie $7 D049109
- 650 _2
- $a látky ovlivňující centrální nervový systém $x farmakologie $x terapeutické užití $7 D002491
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mezibuněčné signální peptidy a proteiny $x metabolismus $7 D036341
- 650 _2
- $a multipotentní kmenové buňky $x účinky léků $x fyziologie $x transplantace $7 D039902
- 650 _2
- $a neurogeneze $x účinky léků $x fyziologie $7 D055495
- 650 _2
- $a neuroglie $x účinky léků $x fyziologie $7 D009457
- 650 _2
- $a neuroplasticita $x účinky léků $x fyziologie $7 D009473
- 650 _2
- $a oligodendroglie $x účinky léků $x fyziologie $7 D009836
- 650 _2
- $a proteoglykany $x metabolismus $7 D011509
- 650 _2
- $a kmenové buňky $x účinky léků $x fyziologie $7 D013234
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Honsa, Pavel $u Department of Cellular Neurophysiology, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Kriska, Jan $u Department of Cellular Neurophysiology, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Anderova, Miroslava $u Department of Cellular Neurophysiology, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Electronic address: anderova@biomed.cas.cz.
- 773 0_
- $w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 141, č. - (2017), s. 42-55
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28522408 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180521123538 $b ABA008
- 999 __
- $a ok $b bmc $g 1300223 $s 1013439
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 141 $c - $d 42-55 $e 20170515 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
- LZP __
- $a Pubmed-20180515